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Organism envy afflicts most researchers who work on
aging in mice; how frustrating it is to see the worm and
fly biologists nail down milestone after milestone,
citation after citation! Surely genetic trickery can produce
mice that age in a comparable jiffy? Alas, our near-total
ignorance of what times the aging process makes it hard





. Building a case that a given short-lived
mutant ages quickly is a steep and thorny path, requiring
more than just plucking a symptom here and there from
a list of things that sometimes go wrong in old people
or old mice. The hallmark of aging is that a lot goes wrong
more or less at the same time, in 2-year-old mice, 10-year-
old dogs and 70-year-old people. Finding ways to damage
one or two systems in a 6-week or 6-month-old mouse
is not too hard to do, but the implications of such studies




 are at best
indirect and at worst imaginary and distracting.





Tired of working with
Slow-aging beasts
Lops out one deoxy-
Ribonucleotide;
Now his mice age just as
Quickly as yeasts.





There is a long and distinguished tradition of mistaking mortality
risk for aging. On balance, people would rather not die; if they
must, they would prefer to do so later rather than sooner. The
obituary pages are devoted mostly to people who die at ages
most readers have not yet reached, because the risk of mortality
goes up almost exponentially with age in a modern society. The
close association between death and aging is so obvious that
children incorporate it into their fundamental models of life and
its trajectories, and when these children grow up into scientists,
it remains all too easy to assume that analyses of lifespan are,
for all practical purposes, analyses of aging.
Modern biological gerontology has, through its historical
development, made the conceptual disentanglement of aging
and mortality more, rather than less, difficult. Textbooks and
handbooks of biological aging research always include a
chapter, very early on, that presents a demographer’s view of aging,
complete with Gompertz curves and discussions of the pros and
cons of various ways to summarize life history tables, as though
the only really useful measure of aging were a count of dead bodies
at specific ages. Students are taught early that claims that a specific
mutation or diet slows aging must be tested by looking for
increased mean or maximal longevity; such evidence is by
cliché and common agreement the ‘gold standard’ against which
other potential measures of diminished aging can be evaluated.
The rationale for this prejudice is a fairly good one: dramatic
postponement of mortality risk is indeed hard to achieve without
modulation of aging, because alterations of risk of any one




., 1990). [‘Hard to achieve’, but not impossible: administration
of clotting factor to a population all of whose members die
of haemophilia would provide a counterexample; see Smith
& Walford (1977) for a real-life example of MHC-mediated
retardation of death in a lymphoma-prone stock of mice.] Use
of age at death as a key outcome measure for comparisons
of aging rate is also sanctioned by the collective failure of the
gerontological community to develop and validate a good series
of surrogate measures (‘biomarkers’) as an alternate index of
aging rate.
If drugs, diets and genes that produce increases in lifespan
act through a delay or deceleration of aging, then it seems plausible
that interventions that diminish lifespan act in the opposite
way, i.e. by acceleration of aging. A moment’s thought shows
this idea to be incorrect, of course: there are uncountable ways
to shorten lifespan, including thousands of mutants that cause
lethal developmental abnormalities, millions of poisons that
kill quickly or slowly, and lots of diets that are just not very good
for you. No one (I hope) would accept a lead-poisoned mouse
or a mouse born without lungs or an immune system as a model
for accelerated aging. Just what should it take to convince a
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us something important about aging, the process that converts
teenagers into seniors, and thence unto dust? How does one
decide that a specific fast-dying mouse merits commitment of
thousands of days and millions of dollars which might instead





When in a cynical mood, I sometimes feel that what it takes
is an ability to overlook the obvious. Consider Fig. 1, which
contains portraits of three old people and someone with a
disease too often represented, to both lay and scientific audiences,
as a form of ‘accelerated’ aging. Portraits emphasize surface
Fig. 1 Portraits of three old people and a person 
with a disease thought to represent accelerated 
aging. Can you spot the ringer? The pictures of 
Frederick Douglass (top right) and Henry Longfellow 
(top left) are reproduced courtesy of The General 
Libraries, The University of Texas at Austin. The 
picture of the child with Hutchinson-Gilford progeria 
is reproduced courtesy of Dr. W. Ted Brown.
Fig. 2 The left panel shows a 24-month-old mouse hemizygous for a mutation encoding a C-terminal fragment of p53. Compared with normal aged mice 
(see right panel) the mutant shows dramatic loss of adiposity and muscle mass and pronounced kyphosis of the spine (Tyner et al., 2002). The middle panel 
shows two 8-week-old mice homozygous for the klotho mutation (Kuro-o et al., 1997). These mice show growth retardation, kyphosis, dysgenesis of external 
genitals in both sexes, an abnormal walking pattern, destruction of the alveoli and arteriosclerosis, none of which is characteristic of normal aged mice. The 
right panel shows, for comparison, an old mouse, age 1420 days, the oldest survivor of a study of wild-derived mice (Miller et al., 2002).
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features and differences in bone modelling, but more detailed
biochemical data would confirm the initial impression: patients
with Hutchinson–Gilford’s disease (so-called ‘progeria’) differ
from normal old people in many ways, lacking many character-
istics of normal aging and presenting many characteristics not
seen among the elderly (Brown, 1991). Figure 2 presents a
similar rogue’s gallery of portraits, this time with a single, easy-to-
identify authentic old mouse easy to spot among poseurs. The
position that these developmental abnormalities are in fact the
same as aging, though conveniently faster, does not withstand
very much scrutiny, and advocates of accelerated aging models
typically now abandon this line of argument if you look them
straight in the eye.
The fallback position, typically, is that the model in question
shows ‘segmental’ aging, i.e. it is like aging in some cells or
organs or systems, though not in all. This is a tougher position
to rebut, in large part because we do not yet know enough
about aging to tell when some abnormality is ‘like aging’ to an
important degree. Old people often have thin skin and fragile bones:
so should a mutation that causes skin atrophy and osteoporosis
be accepted as a model for ‘segmental’ aging? In the absence
of any real knowledge of why old people and old mice develop
skin atrophy and brittle bones, it is possible that an analysis of
mutants that exhibit such signs might shed light on the way in
which aging leads to the same changes. It is at least equally
possible, though, that skin atrophy and brittle bones might
be the end result of many dozens or hundreds of alterations in
genes or metabolic processes that modify turnover and differ-
entiation of connective tissue cells, and that many of these work
in ways quite distinct from the mechanism by which aging
produces the same result. If the mutation in question also
leads to outcomes (examples: a 10-fold increase in mesenchymal
tumours with no corresponding increase in epithelial tumours,
a dramatic increase in UV sensitivity, or exaggerated kyphosis)
not seen in aging bodies, the bet that its detailed analysis will
help us understand the mechanisms of aging becomes progres-
sively riskier. There are many ways to speed up the ‘aging’ of
an automobile, ranging from sugar in the petrol tank to dilution
of motor oil by marinara sauce; analysis of these ‘segmental
automobile aging’ models is not an efficient way to investigate
why Hondas might last longer than Yugos.
A second habit of thought, based on theoretical ideas about
how aging might work, also feeds the passion for models of
accelerated aging. If a scientist has a hunch (often an educated
and justifiable hunch) that aging involves lots of damage to
DNA, then a mutant with poor DNA repair that dies young fairly
calls out ‘study me’ to the pretuned ear. If one then discovers
a few other abnormalities that look like aging, at least in some
respects – premature deafness, or some overlap in liver gene
expression patterns or diminished gonadal function – suspicion
hardens into conviction, the enemy of scientific inquiry. A
proper Popperian would take the opposite tack, looking for
examples in which poor DNA repair, or low levels of Mn-SOD
or poor control of mitochondrial mutation rate do not interfere
with robust health or prevent survival to a ripe old age. Such
hypothesis-testing approaches have done a fine job of disposing
of clever and interesting theories that turned out not to be
correct, such as the proposed association between metabolic rate
and longevity across species (Austad & Fischer, 1991; Miller and
Austad, 1999), and the idea that positive feedback loops might
cause aging by modification of amino acid sequences (Gershon,
1979).
How would one go about proving that a particular mutant,
or a particular drug-treated animal, actually was worth studying
as a model of accelerated aging? Because we do not yet have
any defensible idea of how aging works to produce the
synchronized signs and symptoms of aging, such arguments are
necessarily indirect. A good approach might be to evaluate, in
mutants and controls, a dozen or so well-validated age-dependent
traits in multiple tissues and organs. Do the mutants show
the typical pattern of immune system changes – but earlier? Do
they also show age-dependent changes in muscle fibre type and
motor unit distribution – but earlier? Do they show collagen
cross-linking, altered wound healing, cognitive decline and
changes in two dozen preselected mRNA levels and in IGF-I
levels – but a good deal earlier than controls? Or, alas, do they
simply die at an early age, because of the effects of cardiac



















The caloric restriction (CR) community, trying to make a case
that the CR rodent really does age slowly, has set a superb
example, with now hundreds of tests of the basic claim that
CR rodents show most of the typical signs of aging – but do
so later. Those of us who work with mouse mutants that exhibit
unusually long lifespans are just now beginning to build a
parallel case, with evidence that IGF-I-deficient mice do indeed
show delays not merely in mortality risk, but also in joint changes
(Silberberg, 1972), collagen cross-linking and T-cell subset























., 2003), and only one or




., 2003) dietary interventions,
are known to increase lifespan, and the case that these models





., 2001) in aging rate is already strong and
getting stronger. There are by contrast a vast number of
ways to shorten lifespan, and the claim that a specific member
of this bulging set is an authentic form of speedy aging should
require correspondingly strong support before it receives
comparable commitment of funding, effort and acclaim.
Although the gladiatorial format of the ‘Head-to-Head’ series
encourages advocacy and polemic, scientific decency requires
that one seek a point of balance, rather than mere devastation
of an entire field of endeavour populated largely by one’s
friends, present and former. There is a baby, perhaps several
babies, in the turbid bathwater of the 2026 PubMed references
on ‘accelerated aging’, a literature which grew, in 2002, at the
rate of one published paper every 37 h. For one thing, there
 
Accelerated aging, R. A. Miller




is much to be learned regarding the effects of DNA damage,
telomere length, oxidation damage, abnormal p53 levels, etc., on
cell and developmental biology and pathobiology; high-quality
work on these systems is of high value, whether it is marketed
as ‘aging research’ or not. Aging could well be due (who knows,
really?) to DNA damage, or mitochondrial mutations, or alter-
ations in apoptotic responses or modulations of stem cell
differentiative pathways, and therefore new discoveries in
these areas, however motivated, may well come back someday
to facilitate studies of aging. Second, the synchronicity of age-
dependent changes is a critical puzzle for biogerontology. It is
possible to develop cataracts by age 2 (mice do it), and postpone
sarcopenia until age 60 (we do it); why, then, do horses get
both at about 15–20 years of age, an age at which they also
get serious joint and immune disorders? Some of the more
attractive models advertised as accelerated aging do show
synchronous changes in multiple age-sensitive tissues, and insights
into the mechanism of synchronization might give clues into
parallel mechanisms that work in real aging.
Much of the effort devoted to studies of short-lived mutant
animals (and their human counterparts) is therefore productive
and informative. In my view, however, portraying work in this
area as analysis of ‘accelerated aging’ has two serious conse-
quences. First, it tends to confuse still further the terminological
morass that afflicts discussions of aging, just as the use of the
term ‘cellular aging’ to describe replicative failure of fibroblast
cultures has for years made it more difficult to think about
and discuss the kind of aging that turns young adults into old
people. Second, resources for the study of aging are far lower than
the field deserves, and commitment of funds (and, just as impor-
tantly, the seduction of talented and committed researchers)
to analysis of these malleable and highly marketable model
systems makes it even tougher to make progress in other areas
more likely to produce insights into aging.
As it happens, we already have a fine model for accelerated
aging. It is called the mouse. Like people, mice develop cancer,
cataracts, muscle weakness, immune abnormalities, cognitive
impairment, impaired fertility, joint problems, central obesity,
skin atrophy and myriad other aspects of normal mammalian
aging; but they do so in 2 years rather than 60 years, a full 30-
fold acceleration with none of this ‘segmental’ stuff to worry
about. There are certainly differences between old mice and old
humans, but also unmistakable similarities at the level of cell
biology, tissue organization and systems biology. At the bio-
chemical and histological level, lens, liver, thymus, skin and muscle
biopsies from young adult mice are almost indistinguishable
from biopsies taken from young adult humans, yet one set of
tissues is built to last a few years, and the other many decades.
Elucidation of the factors (telomeric safety valves? altered DNA
repair mechanisms? antioxidant defences? lots of heat-shock
proteins?) that underlie the 30-fold difference in the rate of
progression of a highly overlapping suite of age-dependent
changes should be the number one priority for experimental
gerontologists. This is a lamp-post that not only has the bulb




The impolitic opinions expressed here are my own, but I find it
comforting to remember that at least one other person seems
to agree with many of them: Harrison (1994). I am grateful to
Dr. W. Ted Brown for the charming photograph of the child
with Hutchinson-Gilford syndrome shown in Fig. 1. The long-
lived mouse shown in Fig. 2 enjoyed free room and board for
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